Sleep drug tasimelteon tested for Dream-Acting disorder
NCT ID NCT05922995
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether the sleep drug tasimelteon (Hetlioz) could reduce dream-enactment events in people with REM behavior disorder. Twenty participants took a nightly 20 mg capsule and tracked their symptoms in a daily diary. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tasimelteon (Hetlioz)
- What this could lead to
- If it works, this could point toward a treatment to reduce dream-enactment episodes in REM behavior disorder.
- What could go wrong
- This was a very small, early pilot study that was terminated, so results are limited. It may not show clear benefit or be generalizable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REM BEHAVIOR DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.